Bayer's Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

Core Insights - Bayer announced the FDA approval of Lynkuet® (elinzanetant) 60mg capsules, marking it as the first and only dual neurokinin targeted therapy for treating moderate to severe hot flashes due to menopause [1] Group 1: Product Details - Lynkuet® functions as a neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist [1] - The therapy works by inhibiting Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons [1]